Chairman Message

Message from the Chairman

To Our Valued Supporters

On January 29, 2025, following approval at the Annual General Meeting of Shareholders and the subsequent Board of Directors meeting, I once again assumed the responsibility of leading the Company as Representative Chairman of the Board. Since founding CellSource, I, along with other members of the Company, have remained committed to advancing the practical application of regenerative medicine across society. Now, as I return to the forefront of management, I am determined to accelerate this endeavor even further.

This leadership transition is designed to strengthen our strategies for continuing to explore new business opportunities and focusing on driving further technological innovation. It marks a crucial step in propelling CellSource into its next phase of growth. The healthcare industry is constantly evolving, requiring a swift and agile approach to business development. To stay ahead, our management team must make decisions faster than ever.

In this environment, I will draw on my technological knowledge and expertise as a physician to strengthen R&D and accelerate the integration of regenerative medicine into healthcare on a societal level. By pressing forward with necessary transformations without delay and continuously embracing new challenges, I am committed to achieving groundbreaking results.

With Japan’s rapidly aging population, the importance of preventive medicine and lifestyle improvement is greater than ever. Our mission goes beyond delivering cutting-edge medical technologies through self-funded healthcare; by expanding our clinical network and establishing a data-driven healthcare framework, we aim to build a platform for advancing regenerative medicine in orthopedics and moreover, revolutionize the healthcare delivery model itself.

By advancing the development of patient-centered medical services and R&D of innovative medical technologies, we will strive to establish a truly unique presence in society. To bring innovative medical technologies into real-world application, we will adapt our strategies flexibly to market conditions and technological advancements, making necessary course corrections along the way. As I assumed the role of Representative Chairman of the Board, I have reaffirmed this strategic direction with the current management team. Through this approach, we will accelerate our growth as a new kind of biotech startup.

Another key mission for us is to expand CellSource’s resources—currently concentrated in Japan—along with our accumulated expertise and technologies, into overseas markets and other regions and medical fields where they are needed, contributing to the broader advancement of healthcare. I also believe I can fully leverage my expertise in laying the foundation for CellSource’s growth as a global leader in regenerative medicine. In pursuit of this goal, we will begin preparations for CellSource’s full-scale re-entry into the global market.

CellSource is entering a new phase of growth. Guided by our vision, we will remain committed to delivering patient-centric healthcare and shaping a future where more people can benefit from advanced medical technologies. We will build on our existing strategies and continue taking on new challenges under our renewed leadership structure to drive our growth to the next level. As one unified team, we at CellSource will dedicate ourselves to creating even greater value for society.

We sincerely appreciate your continued support and understanding.